AiPD: Autoinhibited Protein Database

Q16763

Gene name	UBE2S (E2EPF, OK/SW-cl.73)
Protein name	Ubiquitin-conjugating enzyme E2 S
Names	EC 2.3.2.23 , E2 ubiquitin-conjugating enzyme S , E2-EPF , Ubiquitin carrier protein S , Ubiquitin-conjugating enzyme E2-24 kDa , Ubiquitin-conjugating enzyme E2-EPF5 , Ubiquitin-protein ligase S
Species	Homo sapiens (Human)
KEGG Pathway	hsa:27338
EC number	2.3.2.23: Aminoacyltransferases
Protein Class	UBIQUITIN-CONJUGATING ENZYME E2 (PTHR24067)

Descriptions

Ubiquitin conjugating enzyme E2 S (UBE2S) is a protein that plays a key role in accepting ubiquitin from the E1 complex and catalyzing its covalent attachment to other proteins. Dimerization regulates UBE2S by preventing autoubiquitination, thus stabilizing the protein and allowing it to inhibit premature ubiquitin chain elongation during the cell cycle. The autoinhibition is mediated by blocking the ubiquitin-binding sites in UBC domain, which are essential for its E2 activity. The C-helix of UBE2S engages the APC/C for chain elongation, blocking the promotion of UBE2S autoinhibition through dimerization achieved by C-helix.

Autoinhibitory domains (AIDs)

Target domain	1-156 (UBC domain)
Relief mechanism	PTM
Assay	Structural analysis, Mutagenesis experiment

AID

197-222 (C-helix)

Target domain

1-156 (UBC domain)

Relief mechanism

PTM (Substrate autoubiquitination at C-helix)

Assay

Structural analysis, Mutagenesis experiment

Accessory elements

No accessory elements

References

Holliday MJ et al. (2019) "Structures of autoinhibited and polymerized forms of CARD9 reveal mechanisms of CARD9 and CARD11 activation", Nature communications, 10, 3070

Liess AKL et al. (2020) "Dimerization regulates the human APC/C-associated ubiquitin-conjugating enzyme UBE2S", Science signaling, 13,

Bremm A (2020) "Hug and hold tight: Dimerization controls the turnover of the ubiquitin-conjugating enzyme UBE2S", Science signaling, 13,

Autoinhibited structure

Activated structure

10 structures for Q16763

Entry ID	Method	Resolution	Chain	Position	Source
1ZDN	X-ray	193 A	A/B	1-156	PDB
5BNB	X-ray	249 A	A/B/C/D	1-156	PDB
5L9T	EM	640 A	T	1-222	PDB
6QH3	X-ray	290 A	A/B	1-156	PDB
6QHK	X-ray	196 A	A/B	1-156	PDB
6S96	X-ray	218 A	A/B	1-156	PDB
6S98	X-ray	155 A	A/B	1-156	PDB
7AHF	X-ray	215 A	A/B	1-156	PDB
8TAU	EM	350 A	E	205-222	PDB
AF-Q16763-F1	Predicted				AlphaFoldDB

224 variants for Q16763

Variant ID(s)	Position	Change	Description	Diseaes Association	Provenance
rs756893985	4	N>I		No	ExAC TOPMed gnomAD
rs756893985	4	N>S		No	ExAC TOPMed gnomAD
rs756893985	4	N>T		No	ExAC TOPMed gnomAD
rs2090099963	5	V>M		No	TOPMed gnomAD
rs1452269907	9	P>A		No	TOPMed gnomAD
rs552136391	9	P>L		No	gnomAD
rs552136391	9	P>R		No	gnomAD
rs1452269907	9	P>S		No	TOPMed gnomAD
rs1453830867	10	P>L		No	gnomAD
COSM6152223	13	I>F	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1195786947	13	I>T		No	gnomAD
rs374069290 COSM4921770	14	R>C	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic ESP NCI-TCGA TOPMed
rs150992671	14	R>L		No	ESP ExAC TOPMed gnomAD
rs374069290	14	R>S		No	ESP TOPMed
rs531211876	15	L>V		No	1000Genomes ExAC TOPMed gnomAD
rs921581783	18	K>E		No	TOPMed
rs1568442369	19	E>V		No	Ensembl
rs767514205	21	T>A		No	ExAC TOPMed gnomAD
rs762040182	21	T>M		No	ExAC TOPMed gnomAD
rs2123317306	22	T>I		No	Ensembl
rs370647044	23	L>V		No	ESP
rs1308392428	24	T>I		No	TOPMed gnomAD
rs1030465280	25	A>T		No	TOPMed gnomAD
rs1234661620	26	D>E		No	gnomAD
rs1288541692	27	P>L		No	TOPMed gnomAD
rs2090099388	29	D>N		No	TOPMed
rs762797582	34	F>L		No	ExAC TOPMed gnomAD
rs2090099325	35	P>A		No	Ensembl
rs2090099325	35	P>S		No	Ensembl
rs1286125979	36	N>I		No	TOPMed gnomAD
rs139337996	36	N>K		No	1000Genomes ExAC TOPMed gnomAD
rs376302634	37	E>G		No	ESP ExAC TOPMed gnomAD
rs1299385628	37	E>K	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA TOPMed gnomAD
rs745825218	38	E>D		No	ExAC TOPMed gnomAD
rs770350118	39	D>G		No	ExAC TOPMed gnomAD
rs780705474	39	D>H		No	ExAC TOPMed gnomAD
rs770350118	39	D>V		No	ExAC TOPMed gnomAD
rs997693683	40	L>H		No	Ensembl
rs1251231304	40	L>V		No	TOPMed
rs1439506585	41	T>S		No	TOPMed gnomAD
rs2090099057	45	V>I		No	TOPMed
rs187433678	46	T>A		No	1000Genomes
rs2090099014	48	E>K		No	TOPMed gnomAD
rs2090083578	52	G>E		No	Ensembl
rs746549935	52	G>W		No	ExAC gnomAD
rs1286505172	59	L>V		No	gnomAD
rs2090083485	60	F>S		No	gnomAD
rs747823368	61	R>C		No	ExAC gnomAD
rs780505915	61	R>H		No	ExAC TOPMed gnomAD
rs1402132763	62	M>I		No	TOPMed
rs2090083430	62	M>L		No	TOPMed
rs868786422	63	K>E		No	Ensembl
rs1415474642	63	K>T		No	TOPMed gnomAD
rs1265652780	71	P>L		No	gnomAD
rs2090083301	72	A>D		No	Ensembl
rs1393368757	73	S>F		No	TOPMed gnomAD
rs2090083229	76	K>R		No	TOPMed
rs2090083194	78	Y>F		No	TOPMed
rs1308036650	80	L>V		No	TOPMed gnomAD
rs781611407	86	P>L		No	ExAC TOPMed gnomAD
rs758572803	88	V>M		No	ExAC gnomAD
rs1049501918	89	G>V		No	Ensembl
rs765011011 COSM3797556	90	A>S	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic ExAC TOPMed gnomAD
rs765011011	90	A>T		No	ExAC TOPMed gnomAD
rs2090082886	91	N>H		No	gnomAD
rs540315809	91	N>S		No	1000Genomes ExAC TOPMed gnomAD
rs766266228	92	G>D		No	ExAC gnomAD
COSM5572035 rs1350509514	96	V>I	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic NCI-TCGA TOPMed gnomAD
rs1439694374	97	N>S		No	TOPMed gnomAD
rs747733579	98	V>M	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	ExAC NCI-TCGA TOPMed gnomAD
rs2090082726	100	K>E		No	gnomAD
rs774217206	100	K>R		No	ExAC gnomAD
rs770184703	102	D>E		No	ExAC gnomAD
TCGA novel	102	D>N	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs2090082684	104	T>M		No	TOPMed
TCGA novel	105	A>T	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs781704539	108	G>D		No	ExAC gnomAD
rs1400054219	110	R>*		No	TOPMed gnomAD
rs1382629460	111	H>Q		No	TOPMed gnomAD
rs1330328877	112	V>A		No	TOPMed gnomAD
rs771304310	112	V>I		No	ExAC TOPMed gnomAD
rs2090060796	115	T>I		No	Ensembl
rs1600318089	115	T>P		No	Ensembl
rs573318166	117	K>R		No	1000Genomes ExAC TOPMed gnomAD
rs1600318065	122	H>P		No	Ensembl
rs2090060677	123	P>A		No	TOPMed
rs1600318061	124	N>T		No	Ensembl
rs746917958	125	P>A		No	ExAC gnomAD
rs370428278	126	E>K		No	ESP ExAC TOPMed gnomAD
rs1395975605	129	L>F		No	gnomAD
rs764747972	130	N>S		No	ExAC gnomAD
rs753488671	131	E>*		No	ExAC TOPMed gnomAD
rs753488671	131	E>K		No	ExAC TOPMed gnomAD
rs1471768723	133	A>T		No	gnomAD
rs1369706768	133	A>V	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA gnomAD
rs1600317988	134	G>A		No	Ensembl
rs2090060274	134	G>S		No	TOPMed
rs1235935851	135	R>C	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA gnomAD
rs762293175 COSM4127907	135	R>H	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic ExAC NCI-TCGA gnomAD
rs2090060157	136	L>P		No	TOPMed gnomAD
rs763404918	138	L>F		No	ExAC gnomAD
rs1569048131	140	N>D		No	Ensembl
rs775594881	141	Y>C		No	ExAC TOPMed gnomAD
rs775594881	141	Y>S		No	ExAC TOPMed gnomAD
rs2090060028	142	E>G		No	TOPMed
rs759766193	142	E>K		No	ExAC gnomAD
rs759766193	142	E>Q		No	ExAC gnomAD
rs374167114	145	A>T		No	ESP gnomAD
rs1357491467	145	A>V		No	TOPMed gnomAD
rs2090059924	146	A>T		No	TOPMed
rs771995980	147	R>P		No	ExAC TOPMed gnomAD
rs771995980	147	R>Q		No	ExAC TOPMed gnomAD
rs777458627	147	R>W	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	ExAC NCI-TCGA gnomAD
rs748048525	148	A>S		No	ExAC
rs778323528	149	R>C		No	ExAC TOPMed gnomAD
rs754546129	149	R>H		No	ExAC TOPMed gnomAD
rs757533997	155	H>Y		No	ExAC gnomAD
rs1292690585	156	G>R		No	gnomAD
rs753261540	157	G>C		No	ExAC TOPMed gnomAD
rs765404886	157	G>D		No	ExAC gnomAD
rs753261540	157	G>S		No	ExAC TOPMed gnomAD
rs771143319	158	A>D		No	ExAC gnomAD
rs556845857	158	A>T		No	1000Genomes ExAC TOPMed gnomAD
TCGA novel	158	A>V	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA
rs1312646281	159	G>A		No	TOPMed gnomAD
rs773001900	159	G>S		No	ExAC TOPMed gnomAD
rs1312646281	159	G>V		No	TOPMed gnomAD
rs200933021	160	G>R		No	1000Genomes ExAC TOPMed gnomAD
rs768128796	161	P>L		No	ExAC TOPMed gnomAD
rs768128796	161	P>R		No	ExAC TOPMed gnomAD
rs778875694	161	P>S		No	ExAC
rs1207684429	162	S>G		No	TOPMed
rs748838927	162	S>R		No	ExAC TOPMed gnomAD
rs750061593	163	G>C		No	ExAC TOPMed gnomAD
rs750061593	163	G>R		No	ExAC TOPMed gnomAD
rs750061593	163	G>S		No	ExAC TOPMed gnomAD
rs778132592	163	G>V		No	ExAC gnomAD
rs758756486	165	A>T		No	ExAC TOPMed gnomAD
rs765896389	166	E>K		No	ExAC TOPMed gnomAD
rs1034316727	167	A>S		No	Ensembl
rs766382400	168	G>D		No	ExAC TOPMed gnomAD
rs753918789	168	G>S		No	ExAC TOPMed gnomAD
rs766382400	168	G>V		No	ExAC TOPMed gnomAD
rs767327662	169	R>G		No	ExAC TOPMed gnomAD
rs534399153	169	R>P		No	1000Genomes ExAC TOPMed gnomAD
rs534399153	169	R>Q		No	1000Genomes ExAC TOPMed gnomAD
rs767327662	169	R>W		No	ExAC TOPMed gnomAD
rs774238958	170	A>T		No	ExAC TOPMed gnomAD
rs1217946445	170	A>V		No	gnomAD
rs1338267762	172	A>T		No	TOPMed gnomAD
rs768543897	173	S>G		No	ExAC gnomAD
rs1306615876	173	S>N		No	TOPMed
rs768543897	173	S>R		No	ExAC gnomAD
rs749248836	174	G>D		No	ExAC gnomAD
rs749248836	174	G>V		No	ExAC gnomAD
rs2090058877	175	T>I		No	Ensembl
RCV000950018 rs61748180	176	E>A		No	ClinVar 1000Genomes ExAC TOPMed dbSNP gnomAD
rs745530942	177	A>D		No	ExAC TOPMed gnomAD
rs1415815212	177	A>T		No	TOPMed gnomAD
rs745530942	177	A>V		No	ExAC TOPMed gnomAD
rs780766273	179	S>C		No	ExAC gnomAD
rs780766273	179	S>F		No	ExAC gnomAD
rs377751817	181	D>N		No	1000Genomes ESP ExAC TOPMed gnomAD
rs779440236	182	P>S		No	ExAC TOPMed gnomAD
rs755484248	183	G>R		No	ExAC gnomAD
rs2090058568	184	A>T		No	TOPMed gnomAD
rs1373745648	184	A>V		No	gnomAD
rs1212921567	185	P>A		No	TOPMed gnomAD
rs766472486	186	G>R		No	ExAC TOPMed gnomAD
rs762051776	187	G>A		No	ExAC TOPMed gnomAD
rs2090058388	187	G>C		No	TOPMed
rs762051776	187	G>D		No	ExAC TOPMed gnomAD
rs2090058388	187	G>S		No	TOPMed
rs762051776	187	G>V		No	ExAC TOPMed gnomAD
rs201696148	188	P>L		No	1000Genomes ExAC TOPMed gnomAD
rs201696148	188	P>Q		No	1000Genomes ExAC TOPMed gnomAD
rs953767072	188	P>S	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA gnomAD
rs762811480	189	G>E		No	ExAC gnomAD
rs1281856284	189	G>R		No	gnomAD
rs897520466 COSM3539451	190	G>R	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic NCI-TCGA gnomAD
rs745422668	192	E>K		No	ExAC gnomAD
COSM6152224	193	G>D	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	NCI-TCGA Cosmic
rs1318615162	193	G>V		No	TOPMed gnomAD
rs2090058018	195	M>I		No	TOPMed gnomAD
rs746669366	195	M>T		No	ExAC gnomAD
rs770655715	195	M>V	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	ExAC NCI-TCGA gnomAD
rs1437182817	196	A>T		No	TOPMed
rs2090057914	199	H>R		No	TOPMed
rs994456561	199	H>Y		No	TOPMed gnomAD
rs1005962215	201	G>V		No	Ensembl
rs749798764	202	E>K		No	ExAC TOPMed gnomAD
rs780473933	203	R>C		No	ExAC gnomAD
rs756187319	203	R>H		No	ExAC TOPMed gnomAD
rs757414025	204	D>G		No	ExAC TOPMed gnomAD
rs767659246	204	D>H		No	ExAC TOPMed gnomAD
rs767659246	204	D>N		No	ExAC TOPMed gnomAD
rs767659246	204	D>Y		No	ExAC TOPMed gnomAD
rs1379223748	206	K>N		No	gnomAD
rs2090057706	206	K>Q		No	Ensembl
rs1444111571	208	A>T		No	TOPMed gnomAD
rs373412596	208	A>V		No	1000Genomes ESP ExAC TOPMed gnomAD
rs2090057565	209	A>T		No	TOPMed gnomAD
rs762799159	209	A>V		No	ExAC TOPMed gnomAD
rs752661607	211	K>E		No	ExAC TOPMed gnomAD
rs1487657978	211	K>R		No	TOPMed gnomAD
rs1407201235	213	T>A		No	TOPMed gnomAD
rs376584188	213	T>K		No	ESP ExAC TOPMed gnomAD
rs376584188	213	T>M		No	ESP ExAC TOPMed gnomAD
rs1437987468	214	D>E		No	TOPMed gnomAD
rs1600317397	215	K>E		No	Ensembl
rs770567371	216	K>Q		No	ExAC gnomAD
rs528548172	217	R>G		No	1000Genomes ExAC TOPMed gnomAD
rs769119945	217	R>Q		No	ExAC TOPMed gnomAD
rs528548172	217	R>W		No	1000Genomes ExAC TOPMed gnomAD
rs749653893	218	A>S		No	ExAC TOPMed gnomAD
rs780497000	218	A>V	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	ExAC NCI-TCGA gnomAD
rs559435005	220	R>Q	Variant assessed as Somatic; MODERATE impact. [NCI-TCGA]	No	1000Genomes ExAC NCI-TCGA TOPMed gnomAD
rs781182726	220	R>W		No	ExAC gnomAD
rs953632326	221	R>Q		No	TOPMed
rs1311954672	221	R>W		No	gnomAD
rs2090057114	222	L>P		No	Ensembl
rs1392371922	222	L>V		No	gnomAD
rs2123306894	223	L>E		No	Ensembl
rs1294721857	223	L>L		No	Ensembl

No associated diseases with Q16763

2 regional properties for Q16763

Type	Name	Position	InterPro Accession
domain	Ubiquitin-conjugating enzyme E2	11 - 157	IPR000608
active_site	Ubiquitin-conjugating enzyme, active site	84 - 99	IPR023313

Functions

		Description
EC Number	2.3.2.23	Aminoacyltransferases
Subcellular Localization
PANTHER Family	PTHR24067	UBIQUITIN-CONJUGATING ENZYME E2
PANTHER Subfamily	PTHR24067:SF154	UBIQUITIN-CONJUGATING ENZYME E2 G2
PANTHER Protein Class	ubiquitin-protein ligase protein modifying enzyme
PANTHER Pathway Category	Parkinson disease Ubc7 Ubiquitin proteasome pathway E2

4 GO annotations of cellular component

Name	Definition
anaphase-promoting complex	A ubiquitin ligase complex that degrades mitotic cyclins and anaphase inhibitory protein, thereby triggering sister chromatid separation and exit from mitosis. Substrate recognition by APC occurs through degradation signals, the most common of which is termed the Dbox degradation motif, originally discovered in cyclin B.
cytosol	The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
nucleoplasm	That part of the nuclear content other than the chromosomes or the nucleolus.
nucleus	A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.

4 GO annotations of molecular function

Name	Definition
anaphase-promoting complex binding	Binding to an anaphase-promoting complex. A ubiquitin ligase complex that degrades mitotic cyclins and anaphase inhibitory protein, thereby triggering sister chromatid separation and exit from mitosis.
ATP binding	Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.
ubiquitin conjugating enzyme activity	Isoenergetic transfer of ubiquitin from one protein to another via the reaction X-ubiquitin + Y -> Y-ubiquitin + X, where both the X-ubiquitin and Y-ubiquitin linkages are thioester bonds between the C-terminal glycine of ubiquitin and a sulfhydryl side group of a cysteine residue.
ubiquitin-protein transferase activity	Catalysis of the transfer of ubiquitin from one protein to another via the reaction X-Ub + Y --> Y-Ub + X, where both X-Ub and Y-Ub are covalent linkages.

13 GO annotations of biological process

Name	Definition
anaphase-promoting complex-dependent catabolic process	The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, with ubiquitin-protein ligation catalyzed by the anaphase-promoting complex, and mediated by the proteasome.
cell division	The process resulting in division and partitioning of components of a cell to form more cells; may or may not be accompanied by the physical separation of a cell into distinct, individually membrane-bounded daughter cells.
exit from mitosis	The cell cycle transition where a cell leaves M phase and enters a new G1 phase. M phase is the part of the mitotic cell cycle during which mitosis and cytokinesis take place.
free ubiquitin chain polymerization	The process of creating free ubiquitin chains, compounds composed of a large number of ubiquitin monomers. These chains are not conjugated to a protein.
positive regulation of ubiquitin protein ligase activity	Any process that activates or increases the frequency, rate or extent of ubiquitin protein ligase activity.
protein K11-linked ubiquitination	A protein ubiquitination process in which ubiquitin monomers are attached to a protein, and then ubiquitin polymers are formed by linkages between lysine residues at position 11 of the ubiquitin monomers. K11-linked polyubiquitination targets the substrate protein for degradation. The anaphase-promoting complex promotes the degradation of mitotic regulators by assembling K11-linked polyubiquitin chains.
protein K27-linked ubiquitination	A protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 27 of the ubiquitin monomers, is added to a protein.
protein K29-linked ubiquitination	A protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 29 of the ubiquitin monomers, is added to a protein. K29-linked ubiquitination targets the substrate protein for degradation.
protein K6-linked ubiquitination	A protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 6 of the ubiquitin monomers, is added to a protein. K6-linked ubiquitination is involved in DNA repair.
protein K63-linked ubiquitination	A protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 63 of the ubiquitin monomers, is added to a protein. K63-linked ubiquitination does not target the substrate protein for degradation, but is involved in several pathways, notably as a signal to promote error-free DNA postreplication repair.
protein modification process	The covalent alteration of one or more amino acids occurring in proteins, peptides and nascent polypeptides (co-translational, post-translational modifications). Includes the modification of charged tRNAs that are destined to occur in a protein (pre-translation modification).
protein polyubiquitination	Addition of multiple ubiquitin groups to a protein, forming a ubiquitin chain.
ubiquitin-dependent protein catabolic process	The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of a ubiquitin group, or multiple ubiquitin groups, to the protein.

17 homologous proteins in AiPD

UniProt AC	Gene Name	Protein Name	Species	Evidence Code
Q1RML1	UBE2S	Ubiquitin-conjugating enzyme E2 S	Bos taurus (Bovine)	SS
Q9VX25	CG8188	Ubiquitin-conjugating enzyme E2 S	Drosophila melanogaster (Fruit fly)	SS
Q9NPD8	UBE2T	Ubiquitin-conjugating enzyme E2 T	Homo sapiens (Human)	PR
Q96LR5	UBE2E2	Ubiquitin-conjugating enzyme E2 E2	Homo sapiens (Human)	PR
Q969T4	UBE2E3	Ubiquitin-conjugating enzyme E2 E3	Homo sapiens (Human)	PR
Q9Y385	UBE2J1	Ubiquitin-conjugating enzyme E2 J1	Homo sapiens (Human)	PR
Q9H8T0	AKTIP	AKT-interacting protein	Homo sapiens (Human)	PR
P61086	UBE2K	Ubiquitin-conjugating enzyme E2 K	Homo sapiens (Human)	PR
O00762	UBE2C	Ubiquitin-conjugating enzyme E2 C	Homo sapiens (Human)	PR
O14933	UBE2L6	Ubiquitin/ISG15-conjugating enzyme E2 L6	Homo sapiens (Human)	PR
Q7Z7E8	UBE2Q1	Ubiquitin-conjugating enzyme E2 Q1	Homo sapiens (Human)	PR
A1L167	UBE2QL1	Ubiquitin-conjugating enzyme E2Q-like protein 1	Homo sapiens (Human)	PR
Q921J4	Ube2s	Ubiquitin-conjugating enzyme E2 S	Mus musculus (Mouse)	SS
B5DFI8	Ube2s	Ubiquitin-conjugating enzyme E2 S	Rattus norvegicus (Rat)	SS
Q9FF66	UBC22	Ubiquitin-conjugating enzyme E2 22	Arabidopsis thaliana (Mouse-ear cress)	SS
Q28F89	ube2s	Ubiquitin-conjugating enzyme E2 S	Xenopus tropicalis (Western clawed frog) (Silurana tropicalis)	SS
Q4V908	ube2s	Ubiquitin-conjugating enzyme E2 S	Danio rerio (Zebrafish) (Brachydanio rerio)	SS

10	20	30	40	50	60
MNSNVENLPP	HIIRLVYKEV	TTLTADPPDG	IKVFPNEEDL	TDLQVTIEGP	EGTPYAGGLF
70	80	90	100	110	120
RMKLLLGKDF	PASPPKGYFL	TKIFHPNVGA	NGEICVNVLK	RDWTAELGIR	HVLLTIKCLL
130	140	150	160	170	180
IHPNPESALN	EEAGRLLLEN	YEEYAARARL	LTEIHGGAGG	PSGRAEAGRA	LASGTEASST
190	200	210	220
DPGAPGGPGG	AEGPMAKKHA	GERDKKLAAK	KKTDKKRALR	RL